Human EGFR-L858R Stable Cell Line-Ba/F3

Name: Human EGFR-L858R Stable Cell Line-Ba/F3
SKU: CSC-RO0136
Availability: InStock

For research use only. Not intended for any clinical use.

Cat. No. : CSC-RO0136

Host Cell : Ba/F3 Size : >1x10⁶ frozen cells/vial

Inquire for Price

Cell Line Information

Cell Culture Information

Safety and Packaging

Gene Information

Cat. No.	CSC-RO0136
Description	Ba/F3-EGFR-L858R cell line is a stably transfected cell line which expresses human epidermal growth factor receptor (EGFR) with L858R mutation.
Target Gene	EGFR
Gene Species	Homo sapiens (Human)
Host Cell	Ba/F3
Host Cell Species	Mus musculus (Mouse)
Applications	Drug screening and biological assays
Biosafety Level	2
Size	>1x10^6 frozen cells/vial, 1 mL
Stability	Stable in culture over a minimum of 10 passages
Quality Control	Negative for bacteria, yeast, fungi and mycoplasma.
Growth Conditions	37 °C, 5% CO₂
Shipping	Dry ice

Thawing & Subculturing Instructions	1. Thaw cells by gently swirling in a 37°C water bath. To limit contamination, do not submerge the O-ring and cap. 2. When cells are ~70% thawed (~1 min), transfer the vial into a biosafety cabinet, and wipe the surface with 70% ethanol. Allow tube to dry completely. 3. Transfer the cells gently into a 15 mL conical tube containing 10 mL of pre-warmed culture medium (without antibiotic selection marker). Centrifuge cells at ~125 x g for 5~7 min. 4. Remove supernatant without disturbing the pellet, and resuspend cells in 1 mL culture medium (without antibiotic selection marker). Transfer cells to a 6-well plate containing ~2 mL pre-warmed growth medium (without antibiotic selection marker) or a T25 flask containing 5 mL pre-warmed culture medium (without antibiotic selection marker). 5. Incubate the culture at 37°C with 5% CO2. 6. Subculture: split saturated culture 1:4 ~ 1:6 every 3 days; seed out at about 1~3 x 10^5 cells/mL.
Freeze Medium	Frozen with 70% medium, 20% FBS, 10% DMSO
Growth Properties	Suspension, round
Freezing Instructions	Cells are recommended to generate additional frozen stocks at early passages. Frozen stocks should be preserved in a designated cryopreservation medium or in 70% RPMI 1640 + 20% FBS + 10% DMSO (without antibiotic selection marker). 1. Prepare the freezing medium (70% RPMI 1640 + 20% FBS + 10% DMSO, without antibiotic selection marker) fresh immediately before use. 2. Keep the freezing medium on ice and label cryovials. 3. Transfer cells to a sterile, conical centrifuge tube, and count the cells. 4. Centrifuge the cells at 250 x g for 5 minutes at room temperature and carefully aspirate off the medium. 5. Resuspend the cells at a density of at least 3 x10^6 cells/ml in chilled freezing medium. 6. Aliquot 1 ml of the cell suspension into each cryovial. 7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer. 8. Transfer vials to liquid nitrogen for long-term storage.

Mycoplasma	Negative
Format	One frozen vial containing millions of cells
Storage	Liquid nitrogen
Safety Considerations	The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach.
Ship	Dry ice

Gene Name	EGFR epidermal growth factor receptor [ Homo sapiens ]
Gene Symbol	EGFR
Synonyms	ERBB; HER1; mENA; ERBB1; PIG61
Gene Description	epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian)
Gene ID	1956
Uni Prot ID	P00533
m RNA Refseq	NM_005228.3
Protein Refseq	NP_005219.2
Chromosome Location	7p12
Function	ATP binding; MAP kinase kinase kinase activity; actin filament binding; double-stranded DNA binding; enzyme binding; epidermal growth factor-activated receptor activity; epidermal growth factor-activated receptor activity; identical protein binding; contributes_to nitric-oxide synthase regulator activity; protein binding; protein heterodimerization activity; protein phosphatase binding; protein tyrosine kinase activity; protein tyrosine kinase activity; protein tyrosine kinase activity; receptor signaling protein tyrosine kinase activity; transmembrane receptor protein tyrosine kinase activity; transmembrane signaling receptor activity;
Pathway	Adaptive Immune System, organism-specific biosystem; Adherens junction, organism-specific biosystem; Adherens junction, conserved biosystem; Alpha6-Beta4 Integrin Signaling Pathway, organism-specific biosystem; Androgen Receptor Signaling Pathway, organism-specific biosystem; Arf6 signaling events, organism-specific biosystem; Axon guidance, organism-specific biosystem;
MIM	131550

Quick Inquiry

Background

Case Study

Applications

Q & A

Customer Reviews

The L858R mutation in the Human EGFR gene is another point mutation that results in constitutive activation of the EGFR receptor, leading to enhanced cell proliferation and survival. This mutation is commonly found in non-small cell lung cancer (NSCLC) and is associated with resistance to certain EGFR inhibitors.

The Ba/F3 cell line expressing the EGFR-L858R mutation is a valuable tool for studying the effects of this specific mutation on EGFR signaling and its implications for cancer progression. This cell line is particularly useful for drug screening and the development of targeted therapies that can effectively inhibit the activity of the L858R mutant EGFR.

Lung adenocarcinoma frequently harbors mutations in the epidermal growth factor receptor (EGFR) kinase domain, which are critical driver of oncogenesis. Researchers have investigated the unique characteristics of these mutations, particularly focusing on the L858R mutant, which requires asymmetric dimerization for its activation. This dimerization is essential for oncogenic transformation, unlike other mutants such as Ex19Del, Ex20Ins, and L858R/T790M, which demonstrate dimerization-independent activation. Notably, the effectiveness of cetuximab, an EGFR-targeting monoclonal antibody, varies depending on the dimerization dependency of the EGFR mutants, highlighting the need for tailored therapeutic approaches in treating resistant lung cancers.

Figure 1 illustrates Cetuximab inhibits the growth of Ba/F3 cells with the L858R EGFR mutant but has no effect on other oncogenic mutants, while it induces receptor degradation and phosphorylation down-regulation in L858R, Ex19Del, and Ex20Ins mutants, although it does not suppress the growth of resistant H3255GR cells. (doi: 10.1158/0008-5472.CAN-13-1145) Figure 1. The researchers employed Ba/F3 cells transformed with various EGFR mutants, treating them with cetuximab to assess growth suppression and receptor degradation effects. (Cho J, et al., 2013)

Creative Biogene's Human EGFR-L858R Stable Cell Line-Ba/F3 is a valuable tool for exploring these therapeutic avenues. This cell line can serve as a model for investigating the mechanisms of resistance in lung cancer therapies and the efficacy of novel treatments targeting EGFR mutations.

The Human EGFR-L858R Stable Cell Line-Ba/F3 is a cell line that expresses a different mutant form of the EGFR gene (L858R), which is also associated with resistance to EGFR inhibitors. This cell line is useful for similar applications as the EGFR-C797S cell line but provides a different context for studying resistance mechanisms.

（1）Comparative Resistance Studies:

By comparing the EGFR-L858R and EGFR-C797S cell lines, researchers can gain insights into the different mechanisms of resistance to EGFR inhibitors. This comparative analysis can lead to the identification of common and distinct targets for overcoming drug resistance.

（2）Personalized Medicine Approaches:

The EGFR-L858R Stable Cell Line can be used to model patient-specific cancer cells with the L858R mutation. This can help in testing personalized treatment strategies and in understanding the variability in patient response to EGFR-targeted therapies.

（3）Combination Therapy Development:

By studying the effects of the L858R mutation on EGFR function and signaling, researchers can identify potential synergistic effects of combining different drugs to overcome resistance. This cell line can be used to test various drug combinations and their efficacy in inhibiting resistant cancer cells.

Customer Q&As

How does the Human EGFR-L858R Stable Cell Line-Ba/F3 model contribute to our understanding of the mechanisms underlying EGFR mutation-driven oncogenesis?

A: The Human EGFR-L858R Stable Cell Line-Ba/F3 provides a controlled cellular environment to study the oncogenic effects of the EGFR L858R mutation. By observing the behavior of these cells in vitro, researchers can gain insights into how this specific mutation leads to uncontrolled cell growth and proliferation, a hallmark of cancer. This model allows for the assessment of signaling pathways activated by the mutated EGFR and the downstream effects on cell survival, migration, and differentiation, all of which are critical in understanding oncogenesis.

In what ways can the Human EGFR-L858R Stable Cell Line-Ba/F3 be utilized to test the efficacy of novel EGFR tyrosine kinase inhibitors (TKIs) for potential clinical applications?

A: The Human EGFR-L858R Stable Cell Line-Ba/F3 is an excellent model for screening and evaluating the efficacy of new EGFR TKIs. By treating these cells with various concentrations of TKIs, researchers can assess the compounds' ability to inhibit EGFR activity, thereby observing the impact on cell viability, proliferation, and apoptosis. This preclinical testing is crucial for the development of targeted therapies that can effectively treat EGFR-mutated cancers, such as NSCLC.

What are the key genetic and phenotypic characteristics of the Human EGFR-L858R Stable Cell Line-Ba/F3 that differentiate it from other EGFR-mutant cell lines used in cancer research?

A: The Human EGFR-L858R Stable Cell Line-Ba/F3 is distinguished by its stable integration of the L858R mutation in the EGFR gene, which results in a specific activation of downstream signaling pathways. This cell line exhibits increased dependency on EGFR signaling for survival and growth, making it hypersensitive to EGFR inhibition. Additionally, the Ba/F3 background of this cell line provides a unique context for studying the L858R mutation, as it is a hematopoietic cell line that can be easily genetically manipulated, unlike some other cancer cell lines.

How does the Human EGFR-L858R Stable Cell Line-Ba/F3 facilitate the investigation of resistance mechanisms to first-generation EGFR TKIs, and what are the implications for the development of next-generation inhibitors?

A: The Human EGFR-L858R Stable Cell Line-Ba/F3 is instrumental in studying resistance to first-generation EGFR TKIs. By culturing these cells with continuous exposure to these inhibitors, researchers can identify secondary mutations and bypass mechanisms that lead to resistance. Understanding these mechanisms is crucial for the design of second and third-generation EGFR inhibitors that can overcome resistance and provide more effective treatment options for patients with EGFR-mutated cancers.

Can the Human EGFR-L858R Stable Cell Line-Ba/F3 be used to explore the crosstalk between EGFR signaling and other cellular pathways, and how might this influence the development of combination therapies for cancer treatment?

A: Absolutely, the Human EGFR-L858R Stable Cell Line-Ba/F3 is well-suited for investigating the interplay between EGFR signaling and other cellular pathways, such as PI3K/AKT/mTOR and RAS/RAF/MEK. By modulating the activity of these pathways in conjunction with EGFR inhibition, researchers can assess the potential synergistic effects on cell growth and survival. This knowledge is vital for the rational design of combination therapies aimed at enhancing the efficacy of cancer treatments and minimizing the risk of resistance.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Question *

Name

Country *

Email *

Customer Reviews

Optimized for Oncological Testing

This cell line is optimized for testing oncological responses, specifically how cells with the EGFR-L858R mutation respond to various therapies. The Human EGFR-L858R Stable Cell Line - Ba/F3 provides a direct approach to assess the efficacy of treatments aimed at cancers with this mutation.

United States

2021-03-15

Enables Drug Sensitivity Analysis

We can utilize the Human EGFR-L858R Stable Cell Line - Ba/F3 to conduct drug sensitivity analysis, identifying how cancer cells harboring the L858R mutation react to different chemotherapeutic agents. This analysis is crucial for developing personalized medicine strategies for lung cancer patients.

Canada

2021-03-26

Supports Personalized Therapy Development

The cell line aids in the development of personalized therapies by allowing us to test drugs on a specific, clinically relevant mutation. The Human EGFR-L858R Stable Cell Line - Ba/F3 helps in tailoring treatments that are most likely to be effective for patients with the L858R EGFR mutation.

Germany

2024-01-24

Streamlines Molecular Pathway Analysis

The stable expression of the L858R mutation in the Human EGFR-L858R Stable Cell Line - Ba/F3 allows for detailed analysis of the molecular pathways affected by this mutation. We can investigate how the mutation alters EGFR signaling and promotes oncogenic processes, providing insights critical for effective drug design.

Canada

2020-05-06

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Product Name *

Catalog Name *

Rating

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

Product Review Title *

Summary *

Name

Country *

Email *

Related Products

Cat.No.	Product Name	Price
CSC-RO0344	Human ERBB2-G776VC Stable Cell Line - Ba/F3	Inquiry
CSC-RO0317	Human EGFR-K745-E746_ins_IPVAIK Stable Cell Line - Ba/F3	Inquiry
CSC-RO0348	Human KIT-D816Y Stable Cell Line - Ba/F3	Inquiry
CSC-RO0452	Human ERBB2_A775-G776_ins_YVMA Stable Cell Line - MC38	Inquiry
CSC-RO0431	Human METex14Del Stable Cell Line - Ba/F3	Inquiry
CSC-RO0673	Human MERTK Stable Cell Line - THP-1	Inquiry
CSC-RO0745	Human NRAS-Q61K Stable Cell Line - Ba/F3	Inquiry
CSC-RO0316	Human EGFR-V769-D770_ins_GE Stable Cell Line - Ba/F3	Inquiry
CSC-RO0322	Human EGFR-Y764-V765_ins_HH Stable Cell Line - Ba/F3	Inquiry
CSC-RO0352	Human MET-Del14-D1228A Stable Cell Line - Ba/F3	Inquiry

Human EGFR-L858R Stable Cell Line-Ba/F3

Cell Line Information

Cell Culture Information

Safety and Packaging

Gene Information

Background

Case Study

Applications

Q & A

Customer Reviews

How does the Human EGFR-L858R Stable Cell Line-Ba/F3 model contribute to our understanding of the mechanisms underlying EGFR mutation-driven oncogenesis?

In what ways can the Human EGFR-L858R Stable Cell Line-Ba/F3 be utilized to test the efficacy of novel EGFR tyrosine kinase inhibitors (TKIs) for potential clinical applications?

What are the key genetic and phenotypic characteristics of the Human EGFR-L858R Stable Cell Line-Ba/F3 that differentiate it from other EGFR-mutant cell lines used in cancer research?

How does the Human EGFR-L858R Stable Cell Line-Ba/F3 facilitate the investigation of resistance mechanisms to first-generation EGFR TKIs, and what are the implications for the development of next-generation inhibitors?

Can the Human EGFR-L858R Stable Cell Line-Ba/F3 be used to explore the crosstalk between EGFR signaling and other cellular pathways, and how might this influence the development of combination therapies for cancer treatment?

Optimized for Oncological Testing

Enables Drug Sensitivity Analysis

Supports Personalized Therapy Development

Streamlines Molecular Pathway Analysis

Related Products

Related Services